Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-01

Study Completion Date

2023-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to identifying the intramuscular dose equivalent to the 4mg intravenous dose and assess its safety and tolerability as a weekly injection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD

NCT02221622

Mild Cognitive Impairment Alzheimer Disease

COMPLETED PHASE1

Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease

NCT04838301

Alzheimer Dementia Late Onset Alzheimer Disease Neurodegenerative Diseases

RECRUITING PHASE2

Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers

NCT00785759

Alzheimer's Disease Amnestic Mild Cognitive Impairment

COMPLETED PHASE2

Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

NCT06304883

Early Alzheimer's Disease

ACTIVE_NOT_RECRUITING PHASE3

A Study of AMDX-2011P in Participants With Alzheimer's Disease

NCT06514001

Alzheimer Disease

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this bridging study is to advance the therapeutic development of Allopregnanolone (Allo) by using the intramuscular (IM) route of administration as an alternative to the intravenous (IV) route. In order to identify the equivalent IM dose we will conduct pharmacokinetic (PK) analysis previously informed by simulations and modeling. We will recruit a total of 12 participants, both males and females equally distributed, into this single-arm, open-label study.

PK analysis and dose finding will take place for the initial 4 weeks; some participants may not require all 4 weeks of initial dosing to establish maintenance dose. Once maintenance dose is established all participants will receive weekly administration of Allo IM until they complete 12 weeks total of Allo exposure (5 or 6 clinic visits and 6 or 7 home-nurse visits).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Dementia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Single-arm, open-label study

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Allo IM cohort

Allopregnanolone 4-18mg IM, weekly, for 12 weeks.

Group Type EXPERIMENTAL

Allopregnanolone

Intervention Type DRUG

Administration of weekly IM injections of Allopregnanolone.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Allopregnanolone

Administration of weekly IM injections of Allopregnanolone.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Allo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provision of signed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Men or postmenopausal women, aged 55 years or older
* Diagnosis of MCI due to AD or mild AD
* In good general health as evidenced by medical history and with no medical contraindications to participation
* MMSE \> 20 at screen
* Caregiver willing and capable to accompany the patient to clinic visits

Exclusion Criteria

* Daily use of benzodiazepines, sedative/hypnotics, anticonvulsants, antipsychotics, and other drugs that might interact with the GABA-A receptor complex.
* Seizure disorder, history of stroke, focal brain lesion, traumatic brain injury, substance abuse, malignancy.
* Clinically significant laboratory or ECG abnormality obtained at screening visit.
* MRI indicative of significant abnormality, including but not limited to evidence of a single prior hemorrhage or infarct \>1 cm3, multiple lacunar infarcts (\>1) or evidence of a single prior infarct \>1cm3, evidence of a cerebral contusion, encephalomalacia, aneurysms, vascular malformations, subdural hematoma, or space occupying lesions (e.g. abscess or tumor).
* Has any contraindications for MRI studies, including claustrophobia, the presence of metal (ferromagnetic) implants, or a cardiac pacemaker that is not compatible with MRI.
* Is currently enrolled in a clinical trial involving an off-label use of an investigational drug or device, or concurrently enrolled in any other type of medical research or observational study judged not to be scientifically or medically compatible with this study.

Minimum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No